ABSTRACT
An analysis of treatment results was made in 226 patients with multiple isolated intrapulmonary metastases of solid tumors. It appears that surgical removal of metastases was possible in patients with satisfactory functional resources and accurate evaluation in order to validate the indications for surgery. The operation shouldn't result in considerable reduction of quality of life and didn't prevent using other methods of treatment such as medicamental and radiation therapy. The indications to surgical intervention have to be set as individual in consideration of the number of metastases and potential of the patient to undergo the surgery.
Subject(s)
Lung Neoplasms , Lung , Pneumonectomy , Aged , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Lung/pathology , Lung/surgery , Lung Neoplasms/pathology , Lung Neoplasms/physiopathology , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Male , Middle Aged , Neoplasm Metastasis , Pneumonectomy/adverse effects , Pneumonectomy/methods , Postoperative Period , Treatment OutcomeABSTRACT
An analysis of results of 498 patients with malignant pleural effusion was made. All patients were divided into three groups depending on methods of treatment: in the first group of patients the puncture of pleural cavity and the evacuation of liquid were made against the background of complex treatment; in the second group of patients the thoracocentesis and suspension induction were performed; in the third group the video thoracoscopy was carried out. In an assessment of each method of treatment, the researchers came to the conclusion that in case when the patient had the sufficient functional capabilities, the doctors should give preference to the thoracoscopy operations and in case of severe somatic status the doctors should give preference to the drainage of pleural cavity with release from exudates and with subsequent introduction of talc as the most effective sclerosing agent.
Subject(s)
Drainage/methods , Pleural Effusion, Malignant/therapy , Pleurodesis/methods , Thoracoscopy , Adult , Aged , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pleural Cavity , Retrospective Studies , Sclerosing Solutions/administration & dosage , Talc/administration & dosage , Treatment OutcomeABSTRACT
Results of treatment of 51 patients with intrapulmonary metastases of renal cancer were analyzed. Surgical interventions in volume of complete cytoreduction were made in 31 of them. All the patients were followed-up after operations at the period from 3 through 68 months. A multi-factor analysis has shown that surgical metastasectomy gives reliably better results of treatment of patients with disseminated renal cancer. Regressive analysis in the group of operated patients has shown that involvement of the lymph nodes of the bronchopulmonary group and mediastinum gave reliably worse results of treatment of this group of patients.
Subject(s)
Kidney Neoplasms/pathology , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Metastasectomy/methods , Palliative Care/methods , Pneumonectomy/methods , Adult , Aged , Biomarkers, Tumor , Carcinoembryonic Antigen/blood , Data Interpretation, Statistical , Female , Humans , Lung Neoplasms/blood , Lung Neoplasms/physiopathology , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Staging , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
The authors investigated the dependence of increasing serum oncomarkers CEA, Cyfra-21, NSE, TU M2-PK on survival in 739 patients with nonsmall cell lung cancer. The tests for the determination of the content of CEA, Cyfra-21, NSE in blood serum have low sensitivity and are of little use for the diagnosis of lung cancer. The tests because of their simplicity and low cost can be used for the detection of groups of patients with preliminarily diagnosed nonsmall cell lung cancer needing additional methods of examination for more exact staging of the disease and exclusion of remote metastases and more active using adjuvant method of treatment. The use of tumor pyruvate kinase can be perspective for clinical oncopulmonology. However, due to its low specificity, further experiences are required for using this oncomarker in the group of patients with nonsmall cell lung cancer.
